



ASX RELEASE

29 May 2013

Novogen CEO to speak at Investor Forum

Novogen CEO, Dr Graham Kelly, will be presenting at the 'Stars in 2013' Investor Forum in Sydney on Tuesday 4th of June 2013.

The details of the Forum and a copy of the presentation are contained on the Company's website www.novogen.com

Novogen also wishes to draw attention to the fact that the website has been modified to cater for the anticipated increase in news flow stemming from the Company's expanded R&D programs. Of particular interest, the medium-term objectives of the Company are now detailed in the Novogen Blue-Print.

Shareholders and other interested parties also are invited on the website to register for an E-news alert facility.

About Novogen

Novogen Ltd is a public Australian biotechnology company whose shares trade on both the Australian Stock Exchange (symbol 'NRT') and NASDAQ (symbol 'NVGN'). The Company is based in Sydney, Australia and is focused on the development of a family of novel anti-cancer drugs based on comprehensive anti-cancer activity against both cancer cells and cancer stem cells. The Company's inaugural drug candidate is CS-6.

About CS-6

CS-6 belongs to a new class of drug candidates intended to treat most forms of cancer in a comprehensive manner, targeting both cancer cells and their progenitor cells, cancer stem cells. CS-6 shows broad anti-proliferative and cytotoxic activity against human cancer cells and ovarian cancer stem cells. CS-6 also has been designed deliberately to meet the major known criteria for crossing the blood-brain barrier, and for that reason is being developed as a first-line for the treatment of glioblastoma multiforme, the main form of primary brain cancer.

Further information

Contact Dr Graham Kelly, Chief Executive Officer.

Tel: 61 2 9476 0344

Fax: 61 2 9476 0388

Mobile: (61) 0429 854 390

16-20 Edgeworth David Ave Hornsby NSW 2077 AUSTRALIA

PO Box 2333 Hornsby Westfield NSW 1635 AUSTRALIA

E: Graham.Kelly@novogen.com

Further information is available on the Company's web site, www.novogen.com